Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects With Advanced and/or Metastatic Hormone Receptor (HR)-Positive, HER2-negative Breast Cancer

NCT04505826 is registered in ClinicalTrials.gov with Olema Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04505826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04505826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects With Advanced and/or Metastatic Hormone Receptor (HR)-Positive, HER2-negative Breast Cancer
Lead sponsor
Olema Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
August 13, 2020
Completion date
July 30, 2024
Enrollment
153 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative breast cancer, hormone receptor positive breast carcinoma